Glenmark Life Sciences Q3 profit rises 1 percent on API strength
Bengaluru: Indian active pharma ingredients maker Glenmark Life Sciences has reported a narrow 1 percent rise in quarterly profit, as growth in its key generic active pharma ingredients (API) segment offset high costs of raw materials.
The Mumbai-based drug maker's profit rose to 1.05 billion rupees ($12.86 million) in the three months ended Dec 31, from 1.04 billion rupees a year ago.
The generic API segment, which contributes to almost 90 percent of the company's revenue, grew 1.8 percent, benefiting from a capacity expansion at the company's Dahej facility, as well as growth in its regulated markets business.
"India, Europe, and Latin America were the main catalysts for growth whereas U.S. witnessed healthy recovery," said chief executive officer Yasir Rawjee.
The expansion for generic API products at the facility was completed with 240 KL capacity and was operational from this quarter.
Read also: Interim relief to Novartis: Delhi HC reinstates Entresto (Sacubitril-Valsartan) patent in India
Growth in this segment managed to offset the 12 percent jump in input cost and 31 percent decline in its contract development and manufacturing organization (CDMO) business.
"CDMO business was sluggish, and we expect it to pick up strongly from the fourth quarter onwards," said Rawjee.
Glenmark Life Sciences, which was spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, posted revenue from operations of 5.41 billion rupees, up 3.5 percent from the previous year.
Glenmark Pharma will report its third quarter results on Feb 10.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd